drugset / Trial / NCT07211802
CKM For Safe Use of SGLT2i in Type 1 Diabetes
Phase 3
Not yet recruiting
52 enrolled
University of California, San Diego
Abbott · collabLexicon Pharmaceuticals · collabNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collabNational Institutes of Health (NIH) · collab
RandomizedCrossoverTriple-blindTreatment
Summary
This research study is being conducted to learn if wearing a combination continuous glucose monitor/continuous ketone monitor (CGM/CKM) can reduce the side effects of taking sotagliflozin (study drug) in people with type 1 diabetes.
Timeline
- Start
- 2026-07-01
- Primary completion
- 2030-07-31
- Completion
- 2030-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sotagliflozin | Small molecule | 200 mg | — |
| Subject | Sotagliflozin | Small molecule | 400 mg | — |